An observational study in Ulcerative Colitis, Crohn's Disease and Inflammatory Bowel Disease (IBD), sponsored by Takeda. Recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-06.
Sponsored by Takeda · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Colitis, Ulcerative by Takeda — 6 open to participants now, 10 under way, 5 of them phase 3. Colitis, Ulcerative · Takeda.
Among the 68 studies in Colitis, Ulcerative by Takeda, this one is the 9th largest by planned enrollment of the 24 observational ones that give a count, is one of 3 that started in 2023, is one of 24 observational ones, and was the 57th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →6 of the 68 studies in Colitis, Ulcerative by Takeda are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States, China, Czechia and 5 more countries
Ages 18–75
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Australia, Belgium and 15 more countries
Ages 2+
By country, each count listing its studies:
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 199 across 552 observational studies indexed under Colitis, Ulcerative.
Median enrollment 240 across the 43 interventional studies, 372 across the 24 observational. Of the 54 that completed or were terminated, 35 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 155 (87%) have results posted.
4 of the studies in Colitis, Ulcerative by Takeda that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
| NCT05428345TakedaA Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 68 studies in Colitis, Ulcerative by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main aim of the study is to observe adult participants in South Korea that are being treated with vedolizumab injected just under the skin (subcutaneous or SC) to treat ulcerative colitis (UC) or Crohn's disease (CD) who have had an in-adequate response with, lost response to, or had too many side effects in response to either conventional therapy or a Tumor Necrosis Factor-alpha (TNF-α) antagonist. This study will observe the side effects and potential benefit to UC and CD participants related to vedolizumab SC treatment with data collection from medical files. There is no treatment involved in this study, this is only an observational review of current collected data relating to adults in South Korea with UC or CD treated with vedolizumab SC.
This is a prospective, non-interventional, post-marketing study of adult participants with moderately to severely active UC or CD, who have had an inadequate response with, lost response to, or were intolerant to conventional therapy or a TNF-α antagonist. This study will evaluate the safety and effectiveness of vedolizumab SC in a routine clinical practice setting under real world condition.
This study will enroll approximately 600 participants. The data will be prospectively collected, at the centers and recorded into electronic case report forms (e-CRFs). All participants will be enrolled in a single observational group:
This multi-center trial will be conducted in South Korea. The overall time for data collection in the study will be approximately 6 years.
This study will enroll participant with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-α antagonist.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants diagnosed with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF-α antagonist and have initiated treatment with vedolizumab in a routine clinical practical setting in South Korea, will be observed prospectively for 52 weeks.
Percentage of Participants With Serious Adverse Events (SAEs)
Time frame: Up to Week 52
Percentage of Participants With Adverse Drug Reactions (ADRs)
Time frame: Up to Week 52
Percentage of Participants With Serious Adverse Drug Reactions (SADRs)
Time frame: Up to Week 52
Percentage of Participants With Adverse Events of Special Interest (AESIs)
Time frame: Up to Week 52
Percentage of Participants With Unexpected Adverse Events (AEs)
Time frame: Up to Week 52
Percentage of Participants With Unexpected ADRs
Time frame: Up to Week 52
Percentage of Participants With UC and CD Who Achieved Clinical Response
Clinical response:reduction of Mayo score of greater than or equal to(\>=)3points and \>=30 percent(%) from baseline score, with an accompanying decrease in rectal bleeding subscore \>=1 point/an absolute rectal bleeding sub-score of less than or equal to(\<=)1 point in UC participants;and reduction of Crohn's Disease Activity Index (CDAI) score \>=70 points from baseline score in CD participants. Total Mayo score measures disease activity of UC;comprise of 4 sections: stool frequency,rectal bleeding,physician rating of disease activity,endoscopic findings. Each graded from 0-3. Total scores range from 0-12.Higher scores indicate more severity.CDAI assesses CD based on clinical signs such as number of liquid stools,abdominal pain,general wellbeing,presence of complications,opiates for diarrhea,presence of abdominal mass, hematocrit. CDAI consist of eight factors,each summed after adjustment with a weighting factor. Total score ranged from 0-600 points.Higher scores indicate more severity.
Time frame: Up to Week 52
Percentage of Participants With UC and CD Who Achieved Clinical Remission
Clinical remission is defined as: total Mayo score \<=2 and no individual sub-score greater than (\>) 1 point in UC participants; and CDAI score less than (\<) 150 points in CD participants. Total Mayo score measures disease activity of UC; comprise of 4 sections: stool frequency, rectal bleeding, physician rating of disease activity, endoscopic findings. Each graded from 0-3. Total scores range from 0-12. Higher scores indicate more severity. CDAI assesses CD based on clinical signs such as number of liquid stools, abdominal pain, general wellbeing, presence of complications, opiates for diarrhea, presence of abdominal mass, hematocrit. CDAI consist of eight factors, each summed after adjustment with a weighting factor. Total score ranged from 0-600 points. Higher scores indicate more severity.
Time frame: Up to Week 52
Percentage of Participants With UC and CD Who Achieved Mucosal Healing
Mucosal healing is defined as: Mayo endoscopic sub-score of \<=1 point in the UC participants; and Crohn's Disease Endoscopic Index of Severity (CDEIS) score \<3.5 points in the CD participants. Mayo score: instrument to measure disease activity of UC; consists of 4 variables: stool frequency, rectal bleeding, physician rating of disease activity, and endoscopic findings. Each graded from 0-3. Total score range of 0-12. Higher scores indicating more severity. CDEIS comprise of 4 sections assessing endoscopic severity of CD in 5 segments: rectum; sigmoid and left colon; transverse colon; right colon; ileum in terms of: deep ulcerations, superficial ulcerations, surface involved by disease and ulcerated surface measured. The presence of ulcerate and non-ulcerated stenosis will be recorded in each segment. CDEIS score range from 0-44 with a higher score indicating greater severity of disease.
Time frame: Up to Week 52
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Started Sep 2023 (actual). Primary completion is estimated for Nov 2027, 50 months after the start.
Of 83 industry-sponsored observational studies under Colitis, Ulcerative, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 72. This study's planned 50 months is above that.
Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.